Seattle-based ZymoGenetics has established a sales team following the FDA's approval of Recothrom -- a biotech form of the human blood-clotting protein thrombin aimed at preventing blood loss during surgery -- to promote the drug to surgeons. One analyst said the drug could attain annual sales of $300 million within three to five years.

Full Story:

Related Summaries